72
Participants
Start Date
March 8, 2022
Primary Completion Date
February 24, 2026
Study Completion Date
February 24, 2029
Ocrelizumab
ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
Marseille Univesity Hospital, Marseille
Caen University Hospital, Caen
Nimes University Hospital, Nîmes
Bordeaux University Hospital, Bordeaux
Montpellier University Hospital, Montpellier
Rennes University Hospital, Rennes
Nantes University hospital, Nantes
Nancy University Hospital, Nancy
Lille University Hospital, Lille
Clermont ferrand University Hospital, Clermont-Ferrand
Bayonne Hospital, Bayonne
Strasbourg University Hospital, Strasbourg
Lyon University Hospital, Lyon
Amiens University Hospital, Amiens
Nice University Hospital, Nice
Centre Hospitalier Universitaire de Nice
OTHER